Effects of antithrombotic drug, Y-20811 on mural thrombus formation and intimal thickening following intimal injury.
Inhibitory effect of Y-20811 on platelet thrombus formation induced by mechanical intimal injury and subsequent intimal fibrous thickening was studied. In the short term experiment, polyethylene tubing was inserted into the rabbit aorta and was drawn out one hour after with or without Y-20811 administration, then the rabbits were sacrificed. In the experiment for the quantitative analysis of platelet adhesion, 51Cr-labeled platelets were used. Radioactivities of 2cm length of the injured segment of the thoracic aorta and the proximal 2cm of the normal segment were measured. Radioactivity of the injured segment was significantly lower in rabbits treated with Y-20811 than the control ones. The mean thickness (area of thrombi/length of injured intima) and the maximal thickness of the mural thrombi in the Y-20811-treated rabbits were significantly lower than those in control rabbits. De-endothelialized area showed raised platelet thrombi in the control group and diffuse thin-layered platelet sheets in Y-20811-treated rabbits. In the long term experiment, polyethylene tubing was indwelled for 24 hours. Rabbits were sacrificed 10 days after drawing out the tubing. Through the experiment Y-20811 was injected intravenously every 24 hours. There was no significant difference between the control group and the Y-20811-treated one in both mean thickness and maximal thickness of the intimal fibromuscular thickening. The experiments indicate that Y-20811 has an inhibitory effect on platelet thrombus formation following intimal injury, but subsequent myointimal thickening is not inhibited by the drug.
Hayashi
T
T
First Department of Pathology, Miyazaki Medical College, Japan.
Asada
Y
Y
Kisanuki
A
A
Sumiyoshi
A
A
D000818:Animals; D001013:Aorta, Thoracic / Q000293:injuries*; D001018:Aortic Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D004730:Endothelium, Vascular / Q000293:injuries* / Q000473:pathology; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005355:Fibrosis; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D007093:Imidazoles; C049966:Y 20811